All In MedTech

Device Trial Radar · NCT06699797

Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Feb 6, 2025

Primary completion

Apr 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Envoy Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Nov 21, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the Acclaim CI works to treat severe to profound sensorineural hearing loss in adults. It was also learn about the safety of the Acclaim CI implant. The main questions it aims to answer are: * Does the Acclaim CI device help participants hear words better compared to before the implants? * What medical problems do participants have after the Acclaim CI device was implanted? Participants will: * Have the Acclaim CI implanted; and * Visit the clinical site for checkups and tests at 1-Month, 3-Months, 6-Months, and at 1-year and 2-years after the device has been turned on.

Conditions

  • Sensori-Neural Deafness
  • Sensorineural Hearing Loss
  • Sensorineural Hearing Loss (Disorder)
  • Sensorineural Hearing Loss, Bilateral
  • Sensorineural Hearing Loss, Profound
  • Sensorineural Hearing Loss, Severe

Interventions

  • Acclaim Cochlear ImplantDevice

    Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In the Safety Set, frequency and severity of device and procedure related adverse events, including device deficiencies, reported through 12-Month post-activationTime frame: From consent to the 1-year follow-up visit

1 more outcomes with a free account

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Neurosciences Ear and Hearing Center

    Tucson, Arizona

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.